Web Stats Provided By Google Analytics

Monday, October 17, 2016

Regeneron And Teva Provide Update On Fasinumab Clinical Development Programs

JERUSALEM & TARRYTOWN, N.Y.-- --Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. today provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study in patients with chronic low back pain. Fasinumab is an investigational Nerve Growth Factor antibody in clinical development for osteoarthritis pain and chronic low back pain.

No comments:

Post a Comment

Popular Tarrytown Roundup Posts